KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) EPS (Basic) (2016 - 2025)

Rigel Pharmaceuticals has reported EPS (Basic) over the past 16 years, most recently at $14.88 for Q4 2025.

  • Quarterly results put EPS (Basic) at $14.88 for Q4 2025, up 1737.04% from a year ago — trailing twelve months through Dec 2025 was $20.4 (up 1960.61% YoY), and the annual figure for FY2025 was $20.4, up 1960.61%.
  • EPS (Basic) for Q4 2025 was $14.88 at Rigel Pharmaceuticals, up from $1.55 in the prior quarter.
  • Over the last five years, EPS (Basic) for RIGL hit a ceiling of $14.88 in Q4 2025 and a floor of -$3.09 in Q4 2022.
  • Median EPS (Basic) over the past 5 years was -$0.08 (2021), compared with a mean of $0.86.
  • Biggest five-year swings in EPS (Basic): crashed 2107.14% in 2022 and later skyrocketed 5650.0% in 2025.
  • Rigel Pharmaceuticals' EPS (Basic) stood at -$0.14 in 2021, then plummeted by 2107.14% to -$3.09 in 2022, then skyrocketed by 101.62% to $0.05 in 2023, then soared by 1520.0% to $0.81 in 2024, then surged by 1737.04% to $14.88 in 2025.
  • The last three reported values for EPS (Basic) were $14.88 (Q4 2025), $1.55 (Q3 2025), and $3.33 (Q2 2025) per Business Quant data.